Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bandwidth Inc (BAND) vs Heron Therapeutics Inc (HRTX) Price & Performance

Bandwidth IncTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Bandwidth Inc vs Heron Therapeutics Inc — how do they compare? Bandwidth Inc trades at $52.07 (market cap $1.66B), while Heron Therapeutics Inc trades at $0.35 (market cap $61.47M). The key difference: Bandwidth Inc is far larger — about 27× Heron Therapeutics Inc's market cap, and Bandwidth Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

BANDHRTX
Market Cap
$1.66B$61.47M
Sector
TechnologyHealth
52-Week High
$78.44$1.49
52-Week Low
$12.82$0.32
Enterprise Value
$2.04B$168.21M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bandwidth Inc

Bandwidth Inc. (BAND) trades at $52.61, down 0.19% today, with a bullish technical trend per moving averages despite overbought RSI signals. Q2 2026 earnings beat expectations with $0.37 EPS, driven by 22% revenue growth and AI-driven communications demand. The company raised its 2026 outlook, highlighting strong enterprise adoption and a record 18.3% adjusted EBITDA margin.

Outlook is positive with 75% analyst buy ratings and a $75.25 consensus price target, but risks include high valuation (EV/EBITDA 34.08) and negative ROE. Earnings growth from AI integration and margin expansion supports upside, though profitability remains thin with a 0.27% net margin projected for 2026.

Heron Therapeutics Inc

HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.

The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bandwidth Inc

Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.

Read more on BAND

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX